# The Role of IntraNasal Insulin in Regulating HepaTic Lipid COntent in HUMANS

> **NCT02164032** · PHASE2 · UNKNOWN · sponsor: **Medical University of Vienna** · enrollment: 20 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Intranasal insulin administration
- **DRUG:** Insulin Dilution Buffer (Novo Nordisk)
- **OTHER:** 1H magnetic resonance spectroscopy

## Key facts

- **NCT ID:** NCT02164032
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09
- **Primary completion:** 2016-07
- **Final completion:** 2016-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02164032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02164032, "The Role of IntraNasal Insulin in Regulating HepaTic Lipid COntent in HUMANS". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02164032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*